LEXINGTON, Mass.--(BUSINESS WIRE)--Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced today the recommendation from the independent Data Monitoring Committee (DMC) that is overseeing the Company’s Phase 3 clinical investigation of elesclomol in metastatic melanoma, the SYMMETRYSM trial. Based on a review of the safety data and a non-futility analysis, the DMC has recommended that the trial should continue.
